-
Mashup Score: 0Advancing Outcomes of Esophageal Cancer Through Early Detection, Clinical Trials, Minimally Invasive Surgery and More - 9 month(s) ago
David Odell, MD on Northwestern Medicine’s approach to treating esophageal cancer, technology and his team’s work to develop of protocols for early detection.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated the safety and efficacy of trastuzumab combined with ramucirumab and paclitaxel as second-line treatment for HER2-positive G/GEJ cancer. PATIENTS AND METHODS Patients with HER2-positive advanced G/GEJ cancer who progressed after first-line treatment with trastuzumab-containing chemotherapy were enrolled from five centers in the Republic of Korea. Patients were administered a 28-day cycle of trastuzumab (once on days 1, 8, 15, and 22: 2 mg/kg followed by 4 mg/kg loading dose), ramucirumab (once on days 1 and 15: 8 mg/kg), and paclitaxel (once on days 1, 8, and 15: dose level 1, 80 mg/m2; or dose level -1, 70 mg/m2). Phase II was conducted with the recommended phase II dose (RP2D). Primary end points were determination of RP2D during phase Ib and investigator-assessed progr
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ESMO Living Guidelines | ESMO - 10 month(s) ago
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma - 10 month(s) ago
The European Medicines Agency has accepted a marketing authorization application seeking the approval of zolbetuximab for first-line treatment of patients with Claudin18.2-positive, HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Individual Patient Meta-analysis of Neoadjuvant Chemotherapy and Chemoradiotherapy for Esophageal or GEJ Carcinoma - The ASCO Post - 10 month(s) ago
In a meta-analysis reported in the Journal of Clinical Oncology, Faron et al found that neoadjuvant chemotherapy and chemoradiotherapy were associated with better survival vs upfront surgery in patients with thoracic esophageal or gastroesophageal junction (GEJ) carcinoma. The study involved investigation of published or unpublished randomized controlled trials closed to accrual before the end of December 2015 that compared at least two of the following strategies: upfront surgery, chemotherapy followed
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma - 10 month(s) ago
The European Medicines Agency has accepted a marketing authorization application seeking the approval of zolbetuximab for first-line treatment of patients with Claudin18.2-positive, HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma - The ASCO Post - 1 year(s) ago
By Matthew Stenger Posted: 5/4/2023 11:04:00 AM Last Updated: 5/4/2023 10:19:05 AM As reported in The Lancet Oncology by Xu et al, an interim analysis of the phase III RATIONALE-306 trial has shown improved overall survival with the addition of the anti–PD-1 antibody tislelizumab to chemotherapy in the…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings from a Phase Ib/II trial (NCT02962063) of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase II trial (NCT05190445) of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Hear from @DavidDOdell about the new technologies, minimally invasive surgery, and #clinicaltrials to improve outcomes for patients with #esophagealcancer at @LurieCancer @NorthwesternMed. Listen to the podcast: https://t.co/ZiVXzUTQwr #esocsm https://t.co/nyW37lMEGx